|
Oct 14
|
High Growth Tech Stocks to Watch in October 2024
|
|
Aug 28
|
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More
|
|
Aug 27
|
High Growth Tech Stocks To Watch In August 2024
|
|
Aug 26
|
Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
|
|
Aug 26
|
Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
|
|
Apr 1
|
Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing
|
|
Feb 7
|
Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
|
|
Dec 30
|
Insider Sell: Rhythm Pharmaceuticals CTO Joseph Shulman Sells 12,941 Shares
|
|
Dec 6
|
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
|
|
Sep 22
|
Rhythm Pharmaceuticals Presents New Data at ESPE 2023
|
|
Sep 19
|
Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity
|
|
Sep 19
|
Companies Like Rhythm Pharmaceuticals (NASDAQ:RYTM) Are In A Position To Invest In Growth
|
|
Sep 8
|
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
|
|
Sep 8
|
Rhythm Pharmaceuticals Announces Update to September Conference Participation
|
|
Sep 6
|
Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome
|
|
Jul 19
|
Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome
|
|
Jul 18
|
Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023
|